Fact CheckerSign in

NCT06805630Active, not recruiting

Urine Methylation Markers in UTUC

Urine-based Methylation Markers in the Diagnosis and Surveillance of Upper Tract Urothelial Carcinoma

Source: ClinicalTrials.gov · Last updated 5 Aug 2026

Brief summary (registry, in English)

This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine samples will be de-identified and sent to Pangea Laboratory LLC for analysis. The results of this test will be compared to the traditional tests in upper tract urothelial cancer, such as cells in the urine and tissue biopsy.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
28 Jan 2025
Start date
7 May 2025
Primary completion date
30 Dec 2026
Lead sponsor
Duke University
NCT number
NCT06805630

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From 7 May 2025 to the primary completion date, 30 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients who do not understand and/or are unwilling to sign a written informed consent

Who the study is looking for

  • \>=18 years
  • Primary UTUC

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Duke University
Coordinator of this site? Confirm its status
DurhamUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.